MedTrace Logo

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT01079325 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2022-05-23

No results posted yet for this study

Summary

The purpose of the study is to evaluate the clinical effects of the investigational drug, SB-509, in subjects with diabetic neuropathy.

Conditions

  • Diabetes Mellitus, Type 1
  • Diabetes Mellitus, Type 2
  • Diabetic Polyneuropathy

Interventions

DRUG

SB-509

SB-509 60 mg, 3 treatments, and 5 months treatment period

OTHER

Saline

Sponsors & Collaborators

  • Juvenile Diabetes Research Foundation

    collaborator OTHER

  • Sangamo Therapeutics

    lead INDUSTRY

Principal Investigators

  • Winson Tang, MD · Sangamo BioSciences, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2015-05-31
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079325 on ClinicalTrials.gov